BNOX

Bionomics Limited (BNOX) | Rumor.io

Bionomics

BNOX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about BNOX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Dec 24

$BNOX was halted, but the author is holding on to see what happens.
The author believes $BNOX has potential due to its cancer stock and US listing, which may attract more institutional buyers.
The author is buying back into $BNOX after the halt, despite previous frustrations with the stock.

Generated by AI

Sentiment

Of the messages about BNOX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100%	100% +18.33
Bearish	0%	0%	0%	0% -18.33

Bullish· Dec 24

$BNOX has the potential to go wild and may reach mid-teens due to institutional buying after listing in the US.
The company's decision to list in the US may attract more money and institutional buyers, which could lead to a significant increase in the stock price.
The stock has a low float, which means it can move quickly with any buys, and may have a high potential for growth, similar to the experience of another stock ($CREV) that increased from $10 to $100.

Bearish· Dec 24

$BNOX has been halted, preventing some investors from selling their shares.
The stock's recent price movements are attributed to a reverse split, which has led to a decline in its value.
The trading system appears to favor institutional investors over retail traders, resulting in difficulties for individuals trying to sell their shares.

Generated by AI

Topics

Of the messages about BNOX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Analysts· Jan 10

Cantor Fitzgerald initiates coverage on Bionomics (BNOX) with an Overweight rating and a price target of $52.
Berenberg initiates coverage on Bionomics (BNOX) with a Buy rating and a price target of $21.
Evercore ISI Group initiates coverage on Bionomics (BNOX) with an Outperform rating and a price target of $17.

Announcements· Nov 30

Bionomics Limited, a biotech company, has filed a form 6-K with the SEC.
The filing is related to the company's ADR program.
The ticker symbol BNOX is associated with Bionomics Limited.

Technical Analysis· Nov 5

Bionomics Limited ($BNOX) has shown technicals going green and a breakout is expected.
A cup and handle formation is visible on the daily 5m chart, with key support at 0.27-0.3 and the next key level to test at 0.47-0.5.
The stock is close to launching, with the.50 break and hold needed to trigger the trend, potentially similar to the pattern seen in SPPL.

Generated by AI

Community

Of the messages about BNOX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	46.51%
Newcomers	—	—	—	53.49%

Regulars· Dec 8

The MACD has triggered a new buy signal for $BNOX, indicating a potential upward momentum for the asset.
The price has broken above the PV1 level of 1.49, and the PV2 level of 2.09 is being tested, suggesting a strong bullish trend.
The EMA50 for $BNOX is currently above the price, indicating a positive trend and supporting the buy signal triggered by the MACD.

Newcomers· Oct 30

New investors are buying into Bionomics Limited, citing a successful trade with the ticker rising from $3.30 to $3.62.
Some newcomers are looking to swing trade BNOX, with one user identifying a potential buying opportunity around the recent high of $6.50.
Another user is focused on the company's upcoming phase 3 studies, which have been agreed upon by the FDA, and are expected to build on positive phase 2 data.

Generated by AI

Also Discussed

Investors talking about BNOX also mention

#	Name	Attention
1	Neuphoria Therapeutics Inc.NEUP	0%0
2	Silo Pharma Inc.SILO	0%new
3	AXLA - Axcella Health Inc.	——
4	noco-noco Inc.NCNC	0%0
5	VS Media Holdings Limited Class A Ordinary SharesVSME	0%+0
6	Femasys Inc.FEMY	0%+0
7	ICCT - iCoreConnect Inc.	——
8	Sera Prognostics, Inc. Class A Common StockSERA	0%0
9	Tempest Therapeutics Inc.TPST	0%+0
10	AWIN - AERWINS Technologies Inc.	——

Bionomics Limited

Location

Social

What share of all stock conversation is about BNOX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Dec 24

$BNOX was halted, but the author is holding on to see what happens.
The author believes $BNOX has potential due to its cancer stock and US listing, which may attract more institutional buyers.
The author is buying back into $BNOX after the halt, despite previous frustrations with the stock.

Generated by AI

Sentiment

Of the messages about BNOX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100%	100% +18.33
Bearish	0%	0%	0%	0% -18.33

Bullish· Dec 24

$BNOX has the potential to go wild and may reach mid-teens due to institutional buying after listing in the US.
The company's decision to list in the US may attract more money and institutional buyers, which could lead to a significant increase in the stock price.
The stock has a low float, which means it can move quickly with any buys, and may have a high potential for growth, similar to the experience of another stock ($CREV) that increased from $10 to $100.

Bearish· Dec 24

$BNOX has been halted, preventing some investors from selling their shares.
The stock's recent price movements are attributed to a reverse split, which has led to a decline in its value.
The trading system appears to favor institutional investors over retail traders, resulting in difficulties for individuals trying to sell their shares.

Generated by AI

Topics

Of the messages about BNOX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Analysts· Jan 10

Cantor Fitzgerald initiates coverage on Bionomics (BNOX) with an Overweight rating and a price target of $52.
Berenberg initiates coverage on Bionomics (BNOX) with a Buy rating and a price target of $21.
Evercore ISI Group initiates coverage on Bionomics (BNOX) with an Outperform rating and a price target of $17.

Announcements· Nov 30

Bionomics Limited, a biotech company, has filed a form 6-K with the SEC.
The filing is related to the company's ADR program.
The ticker symbol BNOX is associated with Bionomics Limited.

Technical Analysis· Nov 5

Bionomics Limited ($BNOX) has shown technicals going green and a breakout is expected.
A cup and handle formation is visible on the daily 5m chart, with key support at 0.27-0.3 and the next key level to test at 0.47-0.5.
The stock is close to launching, with the.50 break and hold needed to trigger the trend, potentially similar to the pattern seen in SPPL.

Generated by AI

Community

Of the messages about BNOX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	46.51%
Newcomers	—	—	—	53.49%

Regulars· Dec 8

The MACD has triggered a new buy signal for $BNOX, indicating a potential upward momentum for the asset.
The price has broken above the PV1 level of 1.49, and the PV2 level of 2.09 is being tested, suggesting a strong bullish trend.
The EMA50 for $BNOX is currently above the price, indicating a positive trend and supporting the buy signal triggered by the MACD.

Newcomers· Oct 30

New investors are buying into Bionomics Limited, citing a successful trade with the ticker rising from $3.30 to $3.62.
Some newcomers are looking to swing trade BNOX, with one user identifying a potential buying opportunity around the recent high of $6.50.
Another user is focused on the company's upcoming phase 3 studies, which have been agreed upon by the FDA, and are expected to build on positive phase 2 data.

Generated by AI

Bionomics

Social

Dec 24

Sentiment

Bullish· Dec 24

Bearish· Dec 24

Topics

Analysts· Jan 10

Announcements· Nov 30

Technical Analysis· Nov 5

Community

Regulars· Dec 8

Newcomers· Oct 30

Also Discussed

Bionomics Limited

Company Information

Location

Also Discussed

Social

Dec 24

Sentiment

Bullish· Dec 24

Bearish· Dec 24

Topics

Analysts· Jan 10

Announcements· Nov 30

Technical Analysis· Nov 5

Community

Regulars· Dec 8

Newcomers· Oct 30